Stay updated on Ipragliflozin vs Sitagliptin in T2DM with SU+Met Clinical Trial
Sign up to get notified when there's something new on the Ipragliflozin vs Sitagliptin in T2DM with SU+Met Clinical Trial page.

Latest updates to the Ipragliflozin vs Sitagliptin in T2DM with SU+Met Clinical Trial page
- Check6 days agoChange DetectedAdded the Locations section with the Gyeonggi-do site (Seongnam-si, South Korea) and updated the revision to v3.3.3. Removed the Gyeonggi-do Locations header and the HHS Vulnerability Disclosure link in this update.SummaryDifference0.2%

- Check14 days agoNo Change Detected
- Check21 days agoNo Change Detected
- Check35 days agoChange DetectedThe page shows an updated revision note (Revision: v3.3.2) and the previous revision (Revision: v3.2.0) has been removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check42 days agoChange DetectedRemoved the government funding notice banner that warned about potential delays and updates.SummaryDifference0.4%

- Check57 days agoChange DetectedAdded related topics 'Type 2 diabetes' and 'MedlinePlus Genetics' to the study page.SummaryDifference0.6%

- Check64 days agoChange DetectedThe page no longer displays the condition 'Type 2 diabetes' and the related topic 'MedlinePlus Genetics'. This reduces visibility of the study's focus and related resources for users.SummaryDifference0.2%

- Check78 days agoChange DetectedAdded a new MedlinePlus Genetics topic covering Type 2 diabetes, expanding core content.SummaryDifference0.3%

Stay in the know with updates to Ipragliflozin vs Sitagliptin in T2DM with SU+Met Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ipragliflozin vs Sitagliptin in T2DM with SU+Met Clinical Trial page.